A Cross-Sectional Study on Knowledge and Perceptions of Pharmacovigilance among Pharmacy Students of Selected Tertiary Institutions in Jordan

Purpose: To assess the perceptions and knowledge of pharmacovigilance and adverse drug reactions (ADRs) reporting among Bachelor of Pharmacy (BPharm) and Doctor of Pharmacy (PharmD) students of selected tertiary institutions in Jordan.Methods: A cross-sectional study involving 434 pharmacy students from three different Jordanian universities was conducted from March - April 2014. During the study period, a validated structured questionnaire was administered to the participants to assess their knowledge and perceptions regarding pharmacovigilance and ADRs reporting process.Results: Majority of the students had insufficient awareness and lack of knowledge ofpharmacovigilance and ADRs reporting with a mean knowledge score of 4/10. PharmD students had better knowledge about pharmacovigilance and ADRs reporting system than the BPharm students (knowledge score of 5.4 versus 3.2, respectively; p < 0.001). Also, higher knowledge scores were recorded for public university and fifth-year students (p < 0.001). About two-thirds of the students expressed a positive attitude toward pharmacovigilance and ADRs issues and agreed that they would be willing to report ADRs during their clerkship programme.Conclusion: BPharm and PharmD students have insufficient knowledge of the concept ofpharmacovigilance and ADRs reporting. There is a need to incorporate pharmacovigilance into pharmacy curriculum in order to increase its awareness among pharmacy students as this will positively impact on their practice and enhance public health.Keywords: Pharmacovigilance, Adverse drug reactions reporting, Pharmacy students, Knowledge, Perception, Awareness, Attitud

Clinical Advances of siRNA-Based Nanotherapeutics for Cancer Treatment

Cancer is associated with single or multiple gene defects. Recently, much research has focused on incorporating genetic materials as one of the means to treat various types of carcinomas. RNA interference (RNAi) conveys an alternative genetic approach for cancer patients, especially when conventional medications fail. RNAi involves the inhibition of expression of specific messenger RNA that signals for uncontrollable cell growth and proliferation, most notably with carcinoma cells. This molecular technology is promising as genetic materials allow us to overcome issues associated with chemotherapeutic agents including organ damage associated with severe drug toxicities. Nonetheless, vast challenges impede successful gene therapy application, including low tumor localization, low stability and rapid clearance from the blood circulation. Owing to the limited treatment opportunities for the management of cancer, the development of effective siRNA carrier systems involving nanotherapeutics has been extensively explored. Over the past years, several siRNA nanotherapeutics have undergone a period of clinical investigation, with some demonstrating promising antitumor activities and safety profiles. Extensive observation of siRNA-nanoparticles is necessary to ensure commercial success. Therefore, this review mainly focuses on the progress of siRNAs-loaded nanoparticles that have undergone clinical trials for cancer treatment. The status of the siRNA nanotherapeutics is discussed, allowing comprehensive understanding of their gene-mediated therapeutics